CTX.TO - Crescita Therapeutics Inc.

Toronto - Toronto Delayed Price. Currency in CAD
0.9100
-0.0400 (-4.21%)
At close: 3:11PM EDT
Stock chart is not supported by your current browser
Previous Close0.9500
Open0.9500
Bid0.9000 x 0
Ask0.9100 x 0
Day's Range0.9100 - 0.9500
52 Week Range0.3850 - 1.2300
Volume39,144
Avg. Volume65,989
Market Cap19.125M
Beta (3Y Monthly)2.02
PE Ratio (TTM)3.45
EPS (TTM)0.2640
Earnings DateMar 27, 2019 - Apr 1, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Is Crescita Therapeutics Inc. (TSE:CTX) A High Quality Stock To Own?
    Simply Wall St.

    Is Crescita Therapeutics Inc. (TSE:CTX) A High Quality Stock To Own?

    Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...

  • Before You Buy Crescita Therapeutics Inc. (TSE:CTX), Consider Its Volatility
    Simply Wall St.

    Before You Buy Crescita Therapeutics Inc. (TSE:CTX), Consider Its Volatility

    If you own shares in Crescita Therapeutics Inc. (TSE:CTX) then it's worth thinking about how it contributes to the...

  • CNW Group

    Crescita Reports Profitable 2019 Second Quarter Results

    Crescita Reports Profitable 2019 Second Quarter Results

  • CNW Group

    United States Patent and Trademark Office Issues U.S. Patent Covering an Enhanced Formulation of Pliaglis®

    LAVAL, QC , July 16, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that the United States Patent and Trademark Office ("USPTO") has granted U.S. Patent No. 10,350,180 for an enhanced formulation of Pliaglis® which provides extended patent protection until 2031. "The newly granted U.S. patent further strengthens our intellectual property portfolio," said Serge Verreault , President and CEO of Crescita. Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.

  • PR Newswire

    Crescita Therapeutics to Host Investor Webcast on July 24, 2019

    LAVAL, QC, July 11, 2019 /PRNewswire/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it will host a webcast investor presentation on Wednesday, July 24, at 11:00 AM ET. During the webcast, Serge Verreault, Crescita's President and CEO, will provide an introduction to the Company through a PowerPoint presentation that will cover the key areas of Crescita's business, including an overview of the Company's commercial and pipeline products, patented transdermal delivery technologies, its strategy, as well as growth opportunities.

  • Could Crescita Therapeutics Inc.'s (TSE:CTX) Investor Composition Influence The Stock Price?
    Simply Wall St.

    Could Crescita Therapeutics Inc.'s (TSE:CTX) Investor Composition Influence The Stock Price?

    The big shareholder groups in Crescita Therapeutics Inc. (TSE:CTX) have power over the company. Generally speaking, as...

  • CNW Group

    Crescita Therapeutics Inc. Receives 2nd Instalment of Up-Front Payment of €1.25 Million Following First Commercial Sale of Pliaglis by Cantabria in Italy

    LAVAL, QC , July 4, 2019 /CNW/ - Crescita Therapeutics Inc. ("Crescita" or the "Company") (CTX.TO) (OTC US: CRRTF), a commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today announced that it has received the second instalment of € $1.25 million (~CDN $1.88 million ) of the up-front payment related to the out-licensing of Pliaglis in Italy , France , Spain and Portugal , from its partner, Cantabria Labs. The 2nd instalment was received following the completion of the transition activities from Galderma to Cantabria  leading to the first commercial sale of Pliaglis in Italy by the Cantabria sales team. Crescita (TSX: CTX and OTC US: CRRTF) is a publicly traded, Canadian commercial dermatology company with a portfolio of non-prescription skincare products for the treatment and care of skin conditions and diseases and their symptoms and prescription drug products for the treatment of pain.

  • CNW Group

    Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

    LAVAL, QC , June 26, 2019 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita" or the "Company") announced today that the Toronto Stock Exchange (the "TSX") has approved the Company's intention to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares") as appropriate opportunities arise from time to time. Pursuant to the NCIB notice filed with the TSX, the Company intends to acquire up to a maximum of 1,000,000 Common Shares, or approximately 6% of its public float as of June 26, 2019 for cancellation over the next 12 months.

  • CNW Group

    Crescita Therapeutics Inc. Announces Intention to Make Normal Course Issuer Bid

    LAVAL, QC , June 17, 2019 /CNW/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) ("Crescita" or the "Company"), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it intends to make a normal course issuer bid ("NCIB") for a portion of its common shares ("Common Shares") as appropriate opportunities arise from time to time. The Company's normal course issuer bid, which is expected to be for up to 1,000,000 common shares, or approximately 6% of its public float, will be made in accordance with the requirements of the Toronto Stock Exchange (the "TSX") and remains subject to TSX approval.

  • PR Newswire

    Crescita to Present at the 9th Annual LD Micro Invitational in Los Angeles, California

    LAVAL, QC, May 30, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that its Executive Chairman, Dan Chicoine will be presenting at the 9th annual LD Micro Invitational on Tuesday, June 4th at 3:00 p.m. pacific time. "We are very excited to be presenting at this prestigious conference and we look forward to introducing Crescita to a new list of potential U.S. investors" stated Dan Chicoine, executive chairman. The LD Micro Invitational will take place June 4th and 5th in Los Angeles, at the Luxe Sunset Bel Air Hotel, will feature 230 companies, and will be attended by over 1,000 individuals.

  • PR Newswire

    Crescita Therapeutics Engages Bristol Capital to Provide Investor Relations and Communications Services

    LAVAL, QC, May 29, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, announced today that it has entered into a consulting agreement with Bristol Capital LTD. ("Bristol"), a leading investor relations firm servicing Canadian and US microcap and small cap companies across international markets, to provide investor relations and communication services. Bristol will provide investor relations services to Crescita, including introductions to Bristol's direct network of investment professionals, coordination of public events and proactive investor relations campaigns to increase Crescita's exposure in the investment community.

  • PR Newswire

    Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders

    LAVAL, QC , May 15, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and ...

  • CNW Group

    Crescita Therapeutics Reports 2019 First Quarter Results

    Crescita Therapeutics Reports 2019 First Quarter Results

  • PR Newswire

    Crescita Therapeutics Strengthens Leadership Team with New Vice-President in Aesthetic and Cosmeceutical Business Unit

    LAVAL, QC, May 7, 2019 /PRNewswire/ - Crescita Therapeutics Inc. (CTX.TO) (OTC US: CRRTF) (Crescita or the Company), a Canadian commercial dermatology company with a portfolio of non-prescription skincare products and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, is very pleased to announce that Mr. Jean Colas has joined Crescita as Vice-President of its Aesthetic and Cosmeceutical business unit. Jean's responsibilities will encompass sales team leadership, brand awareness, go-to-market strategy, marketing communications, and customer service. "Jean is a great addition to the Crescita team and knows what it takes to deliver both brand and client success," said Serge Verreault, President and CEO of Crescita.